A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01690871
First received: September 6, 2012
Last updated: August 1, 2013
Last verified: August 2013
  Purpose

Study objectives:

The primary objective is to determine the efficacy of BEZ235 on Objective Response Rate (best response on study) according to RECIST 1.1 criteria

The secondary objectives are:

  • To determine the progression free survival rate at 32 weeks in the included population
  • To assess the duration of response among responders
  • To evaluate time to response
  • To evaluate the time to progression
  • To assess the overall survival
  • To evaluate safety and tolerability of BEZ235

The exploratory objectives are:

  • To identify molecular and genomic profiles of PEComas and their potential relationship to clinical outcome by analyzing PIK3CA, Ras, Raf, TSC, AKT and PTEN alteration in tumor samples (archival or fresh pre-treatment tumor biopsy) and PIK3CA in circulating DNA.
  • To determine biomarkers relevant to BEZ235 activity by analyzing the expression of phosphoproteins p-AKT, p-S6, p-4EBP1 at screening and during treatment as well as biomarkers for the proliferation (Ki-67) and apoptosis (PARP) (only if fresh tissue (optional) is available).

Study population:

The patient population consists of patients 18 years old or older with progressive unresectable/advanced or metastatic malignant PEComas previously treated for unresectable/advanced/metastatic disease with 1 to 2 prior lines of chemotherapy. Patients must have adequate hematologic, renal, cardiac and hepatic functions and not be previously treated with a mTOR inhibitor.

Number of patients:

16 to 33 patients

Overview of study design:

This is a prospective, multicenter, open-label, single arm, two-stage phase II study to investigate the efficacy and tolerability of BEZ235 in patients with progressive metastatic or unresectable/advanced malignant PEComas. The patient should have received 1 or 2 prior lines of chemotherapy.

BEZ235 will be administered until disease progression. Sixteen patients will be enrolled into Stage 1 and observed for at least 32 weeks at which time an interim analysis will be performed (plus eventually 4-5 weeks for confirmation of responses occurring on or closely before this cut-off date). If the number of patients with a response (CR or PR) is 2 or less, the trial will be stopped for futility. If 3 or more patients experience a response enrollment will continue up to 33 patients (Stage 2).

An Independent Data Monitoring Committee (IDMC) will be constituted for reviewing the interim analysis.


Condition Intervention Phase
Malignant PEComa (Perivascular Epithelioid Cell Tumors)
Drug: BEZ235
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Proportion of Patients with best Objective Response Rate (ORR) [ Time Frame: From treatment start to end of follow-up, assessed up to 30 months ] [ Designated as safety issue: No ]
    Objective Response Rate is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR) according to RECIST. 1.1.


Secondary Outcome Measures:
  • Progression Free Survival rate [ Time Frame: 32 weeks ] [ Designated as safety issue: No ]
    Time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.

  • Duration of response [ Time Frame: From Initial response (CR or PR) until objective tumor progression, assessed up to 30 months ] [ Designated as safety issue: No ]
    Duration of response (DR) is measured from the time of initial response (CR or PR) until objective tumor progression.

  • Time to response [ Time Frame: From start of treatment to the initial response, assessed up to 30 months ] [ Designated as safety issue: No ]
    Time to response (TTR) is defined as time from treatment start until initial response (CR, PR)

  • Time to disease progression [ Time Frame: From start of treatment to first documented disease progression assessed up to 30 months ] [ Designated as safety issue: No ]
    Time from date of start of treatment to the date of event defined as the first documented progression or death due to underlying cancer. If a patient has not had an event, time to progression is censored at the date of last adequate tumor assessment.

  • Overall survival [ Time Frame: From start of treatment to date of death (due to any cause) assessed up to 30 months ] [ Designated as safety issue: No ]
    Time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last known date patient alive.

  • Number of Adverse Events as a Measure of Safety and Tolerability [ Time Frame: up to 30 months ] [ Designated as safety issue: Yes ]
    The incidence of treatment-emergent adverse events (new or worsening from baseline) will be summarized by system organ class and or preferred term, severity (based on CTCAE grades), type of adverse event, relation to the study drug. Laboratory data will be graded according to CTCAE version 4.03 if relevant. For laboratory tests where grades are not defined according to CTCAE, abnormalities will be assessed according to laboratory normal ranges.


Enrollment: 0
Study Start Date: September 2012
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BEZ235
BEZ235 will be supplied in 200mg, 300mg and 400mg sachets packaged in boxes. Each box will contain only sachets of one strength.
Drug: BEZ235
Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  1. Histologically confirmed diagnosis of malignant PEComa (included epithelioid AML) of primary disease or of metastatic lesion from archival tissue if it has been obtained within 12 months prior to enrollment in this study. This histological diagnosis includes immunochemistry as follows:

    • Immunohistochemically positive expression of a melanocytic marker (HMB45, MelanA or microphtalmia transcription factor) AND of a smooth muscle marker (smooth muscle actin, pan-muscle actin, h-caldesmon or calponin) is mandatory on primary or metastatic tumor biopsy.
    • Note: According to Folpe (2002), criteria for malignancy in non-AML PEComas are:
    • tumor size of more than 5 cm,
    • infiltrative growth pattern,
    • high nuclear grade,
    • mitotic activity of more than 1/50 high power field (HPF),
    • necrosis,
    • vascular invasion
    • Thus, to be included in the trial, the patient should have tumor presenting with 2 or more criteria for malignancy associated with aggressive clinical behavior.
  2. If the primary diagnosis was performed more than 12 months before enrollment, the histology of a primary/metastatic lesion should be reconfirmed with a fresh biopsy.
  3. Availability of a representative tumor specimen, either archival or fresh tumor tissue for PI3K pathway analysis.
  4. Unresectable/advanced and/or metastatic and documented progressive measurable disease as defined by RECIST 1.1 criteria. Prior to study entry, the progression of the disease should be confirmed by at least 2 sequential CT scans available for documentation (will be collected and hold).
  5. Presence of measurable disease according to RECIST 1.1. Note: Lesions in previously irradiated areas can only be considered measurable if they have clearly progressed since the radiotherapy.
  6. Treated with 1 or 2 prior lines of treatment Exclusion criteria

1. Disease exclusions:

  1. Lymphangioleiomyomatosis (LAM) exclusively
  2. Active uncontrolled or symptomatic CNS metastases Note: A patient with controlled and asymptomatic CNS metastases may participate in this trial. As such, the patient must have completed any prior treatment for CNS metastases > 28 days (including radiotherapy and/or surgery) prior to start of treatment in this study and should not be receiving chronic corticosteroid therapy for the CNS metastases.
  3. Concurrent malignancy or malignancy in the last 3 years prior to start the study treatment (with the exception of adequately treated cervical carcinoma in situ or nonmelanoma skin cancer).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01690871

Locations
Spain
Novartis Investigative Site
Barcelona, Cataluña, Spain, 08025
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01690871     History of Changes
Other Study ID Numbers: CBEZ235ZIC01
Study First Received: September 6, 2012
Last Updated: August 1, 2013
Health Authority: Italy: Ministry of Health
Netherlands: Dutch Health Care Inspectorate
Spain: Ministry of Health
Hungary: Institutional Ethics Committee

Keywords provided by Novartis:
Malignant PEComa
Angiomyolipoma
Tuberous Sclerosis Complex
Pi3kinase /m-tor inhibitors

Additional relevant MeSH terms:
Perivascular Epithelioid Cell Neoplasms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on September 16, 2014